Literature DB >> 31446564

Correction to: Camrelizumab: First Global Approval.

Anthony Markham1, Susan J Keam2.   

Abstract

Page 1355, Abstract, Inline table 'Camrelizumab (AiRuiKa™): Key Points', and Introduction.

Entities:  

Year:  2019        PMID： 31446564     DOI： 10.1007/s40265-019-01191-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  4 in total

1.  Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature.

Authors:  Kai Liu; Jian-Feng Bao; Tao Wang; Hao Yang; Bao-Ping Xu
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

2.  Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report.

Authors:  Luming Zheng; Ling Li; Qingqing He; Meng Wang; Yunhan Ma; Jian Zhu; Yanchen Li; Xiaokang Fu; Yaxuan Zhang
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 3.  Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?

Authors:  Sergio Di Molfetta; Andrea Dotto; Giuseppe Fanciulli; Tullio Florio; Tiziana Feola; Annamaria Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-14       Impact factor: 5.555

4.  Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report.

Authors:  Yao Wang; Ying Gao; Hai-Ruo Chen; Hong Liu; Xi Fu; Ran Yan; Feng-Ming You; Zhuo-Hong Li
Journal:  Clin Med Insights Oncol       Date:  2021-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.